INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) has become the 'standard-of-care' treatment for a variety of nonmalignant disorders (NMD) such as immunodeficiencies, bone marrow failure syndromes (BMFS), inborn errors of metabolism (IEM) and hemoglobinopathies [1 & ,2 & ,3,4]. The majority of hereditary disorders need HCT intervention in the pediatric age group prior to the development of complications. During the past decades, HCT has become safer and better tolerated, resulting in higher disease-free survival. In addition, unrelated and alternative donor sources have made HCT more available to patients in the absence of suitable human leucocyte antigen (HLA)-matched siblings. In the present mini-review, we provide an overview of the advances made in the use of unrelated and alternative donors for HCT and its implications and future perspectives for the treatment of NMD. most patients. Other management options including enzyme replacement therapy (ERT) and gene transfer into autologous hematopoietic stem cells may provide an alternative approach to HCT in specific immune deficiencies.
PID may be broadly divided into severe combined immunodeficiencies (SCID) and non-SCID, including hemophagocytic syndromes and autoimmune and immunoregulatory disorders (Table 1) . Guidelines for HCT for (non)SCID, including detailed protocols, have been produced by the European Society for Blood and Marrow Transplantation (EBMT) Inborn Errors Working Party [5] .
Currently, the outcomes after matched sibling donor (MSD) HCT exceed 90% [1 & ,6]. Sibling donor bone marrow may be infused into SCID recipients without the requirement for conditioning or graft versus host disease (GVHD) prophylaxis. This leads to the rapid development of T-cell and B-cell function after HCT, although usually only T cells of donor origin develop, and myeloid and erythroid cells remain of recipient origin. The majority of patients achieve humoral reconstitution despite lack of donor B cells, although this is dependent on the type of SCID [1 & ,6]. In non-SCID diseases, conditioning is always required for all donor sources. In addition to MSDs, mismatched related (e.g. haploidentical) and unrelated donors (URDs) can be used as alternative donors. In comparison to MSD, these donors have a trend to reduced overall survival [1 & ,6,7]. As the risk of rejection/GVHD is too high for a simple infusion, conditioning and GVHD prophylaxis is recommended. A variety of conditioning regimens have been used, and current recommendations [5] include the use of intravenous busulfan/fludarabine-based or treosulfan/fludarabine-based protocols. Special consideration needs to be made for radiosensitive SCID. Although this does not impact donor choice, it has an impact on the choice of conditioning regimen.
The advantage of haploidentical donors is that virtually all children have a haploidentical parental donor that is readily available. HLA disparity, however, necessitates deep T-cell depletion in order to avoid GVHD. With the introduction of peripheral blood stem cells, centers that prefer haploidentical donors over an unrelated cord blood donor employ CD34 þ cell selection or large-scale CD3/CD19 negative depletion. More recently, a/b-T-cell receptor depletion methods have been employed to a threshold of 1-5 Â 10 4 /kg CD3 þ cells, below which GVHD prophylaxis is not required [8 & ]. Some centers perform such haploidentical HCT without any conditioning. The best results are seen in those transplanted at less than 3.5 months of age and in those with a T À B þ phenotype SCID. A major drawback is that B-cell function is restored in only $20%; others require lifelong immunoglobulin supplementation
]. With conditioning, immune reconstitution is generally better; it is important to take the clinical condition (including comorbidities) into consideration when deciding.
Unrelated cord blood is regarded as another readily available alternative donor source. More than 600 000 cord blood units are stored worldwide. The theoretical advantages of using cord blood as donor source in patients with SCID are rapid availability, no requirement for T-cell depletion (resulting in faster immune reconstitution), lower risk of GVHD compared with adult URDs and a greater proliferative life span that might be particularly important in such young recipients. Disadvantages are (historically) slower engraftment (depending on cell dose infused) and lack of availability of the donor for a boost HCT. In cell source comparison studies [1 & ,9] , cord blood showed similar outcomes compared with other alternative donors. In a recent Eurocord/EBMT haploidentical versus cord blood HCT comparison [9], survival was similar, but the probability of getting off immunoglobulin supplementation was higher in cord blood recipients. In this comparison study, the haploidentical transplants were performed at four specialized haplo-centers in contrast to more than 30 transplant centers proficient in cord blood transplantation (CBT), suggesting that CBT may be more generally applicable.
During the past decade, alternative cell therapies have been developed for PID, gene therapy being the greatest advancement. The first human condition for which gene therapy has shown unequivocal benefit is X-linked severe combined immunodeficiency (SCID-X1) using retroviral-mediated transfer of the IL2RG gene into autologous CD34 þ cells [10]. Nowadays, a variety of PID gene therapy protocols are open; for example, WAS, X-linked chronic granulomatous disease, adenosine-deaminase (ADA), and a few more
KEY POINTS
Availability of alternate donor stem cell sources and successful use in HCT for NMD has expanded curative options for these disorders.
Significant progress has been made toward reducedintensity and reduced-toxicity preparative regimens in HCT for NMD.
It is essential to plan and track short-term and long-term function and outcomes after HCT for the various groups of NMD.
that are in the pipeline will follow soon [11 & ]. Successful reconstitution of cellular and humoral immunity has been demonstrated in the majority of patients treated. So far, more than 60 patients with PID have been treated in gene therapy trials. In the early days, serious side effects were reported related to insertion of the retroviral vector into a protooncogene (LIM domain only 2), resulting in the development of T-cell leukemia in 5 of 20 patients treated in the 2 SCID-X1 gene therapy studies [12] . Modifications to vector design, used in current trials, may overcome the problems associated with these initial trials. The role of gene therapy alongside conventional HCT (or ERT for ADA-SCID) is shown 
INBORN ERRORS OF METABOLISM
IEM comprise an assorted group of inherited diseases, some of which are because of disorders of lysosomal or peroxisomal function that may be benefitted by HCT. In these disorders, onset in infancy or early childhood is typically accompanied by rapid deterioration, resulting in early death in the more severe phenotypes. Timely diagnosis and immediate referral to an IEM specialist are essential steps in optimal management. Treatment recommendations are based on the diagnosis, phenotype, ]. Here, we will focus on cell sources used in HCT in IEM, providing an international perspective on progress, limitations and future directions.
Although this can be argued, mucopolysaccharidosis type 1 (MPS-1;Hurler's disease), which is the most frequently transplanted IEM, is often used as the 'example' disease in the development of guidelines. This is mainly because all other IEM that benefit from HCT are very rare. Until a decade ago, HCT in MPS-1 was limited by high rates of graft failure and transplant-related mortality [14] . International collaborative studies identified predictors for graft failure, including T-cell-depleted grafts and reduced-intensity conditioning (RIC), while busulfan with therapeutic drug monitoring appeared to be a predictor for higher 'event-free survival' in comparison to prior experience [2 & , [14] [15] [16] . These data have led to an EBMT transplant protocol/guide- 17] . These guidelines include standardized myeloablative conditioning regimens (currently fludarabine þ exposure-targeted busulfan) and the use of cord blood as a preferred graft source, second only to noncarrier-matched sibling bone marrow. This transplant protocol with well-matched grafts resulted in significantly improved engraftment and a survival rate of more than 90% in larger experienced HCT centers specialized in transplanting patients with MPS, who also have standardized long-term follow-up programs [18] .
During the past decade, unrelated cord blood has been used with increasing frequency as a graft source for HCT in children with an IEM. Similar to PID, cord blood offers several advantages (see Primary Immunodeficiencies) over bone marrow or peripheral blood, of which reduced time to transplant in neurodegenerative diseases is a very important one. Recent collaborative cell source comparison studies suggest that the highest 'event-free survival rates' are achieved in patients receiving an identical MSD or an identical (6/6) unrelated cord blood, followed by 5/6 matched or 10/10 matched URD. Interestingly, almost all cord blood recipients had full-donor chimerism associated with normal enzymes levels, while mixed chimerism was more frequently seen in matched sibling and matched unrelated donor (MUD) donors
]. It is also important to recognize that most MSDs are carriers, influencing posttransplant enzyme levels, which appear to be important for long-term outcomes, including neurocognitive outcomes [15, 19] .
In 2003, intravenous 'ERT' became available for MPS-1. HCT remains the treatment of choice in patients with the Hurler phenotype of the disease as ERT does not cross the blood-brain barrier. It is however studied in combination with HCT, aiming to reduce the toxicity of the HCT. The combination of ERT and HCT for mucopolysaccharidosis type 1 (MPS IH; Hurler phenotype, similar to MPS-1) children has been evaluated in single-center and multicenter studies and found that although ERT was well tolerated, the combination of ERT and HCT did not affect rates of survival, engraftment or HCT-associated morbidity within the entire cohort [20, 21] . The studied population, however, was not a high-risk population of patients. Patients in a very poor clinical condition, especially those with cardiac dysfunction [22 & ], may improve significantly on ERT, making them eligible for HCT. Currently, many transplant centers are administering ERT to patients with MPS IH prior to HCT and continuing it until either start of the conditioning or achievement of donor-derived engraftment.
As for other NMD, gene therapy protocols are being developed: for example, Biffi and colleagues [23 & ] demonstrated the clinical benefit to such an approach in infantile metachormatic leukodystrophy (MLD). Whether gene therapy is superior to HCT needs to be determined after longer-term follow-up. There are several other similar gene therapy approaches that are quite close to clinical trials (e.g. MPS-3, MPS-1, X-linked adrenoleukodystrophy) [24] [25] [26] . Besides more effectively treating transplant refractory illness, gene therapy may further improve outcomes of currently treated conditions by improving enzyme delivery and by reducing transplant risk (e.g. no GVHD risk). Of course, the efficacy of such an approach should be prospectively evaluated against conventional therapies, especially in terms of safety and long-term stability of gene expression.
BONE MARROW FAILURE SYNDROMES
BMFS may be inherited or acquired. Disorders are listed in Table 2 and . URD HCT outcomes are now similar especially when performed at a young age (<20 years), using RIC incorporating antithymocyte globulin (ATG) or alemtuzumab. The latter has a survival benefit especially and lower GVHD rates (11 versus 25%) [33,34 & ]. Bone marrow is the gold standard as higher GVHD rates are seen with peripheral blood stem cells at all ages [31, 35] . HCT has the advantage over IST that 5-year failure-free survival rates are greater than 85% but less than 60% with IST [36 ]. Standard URD transplants are associated with higher GVHD (24-50%) and TRM (30-39%). Fludarabine-based RIC regimens can successfully offset toxicities and support engraftment [49] . Ex-vivo T-cell depletion to offset GVHD is an alternate strategy [50] . Both T-cell-depleting protocols and unrelated cord blood transplantation (UCBT) are associated with increased graft rejection (39%) compromising DFS (75% bone marrow; 61% cord blood) resulting in the need for increased conditioning, cell dose (>6.1 Â 10 7 /kg) and early HCT (<5 years of age). Progression to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) reduces DFS to 27-57%. RIC approaches are very important in dyskeratosis congenita and Fanconi anemia with DNA susceptibility in which late mortality (OS 49% at 20 years) is high from organ toxicity (hepatic, renal, pulmonary failure) [51, 52] . HCT results are better before clonal evolution and radiation, and when performed at less than 10 years of age. Fludarabine-containing regimens have increased OS to 64% recently, but the probability ] remains a concern. HCT can salvage patients with clonal abnormalities more effectively before established MDS or AML [53 & ].
HEMOGLOBINOPATHIES
There are approximately 100 000 people living with sickle cell disease (SCD) and 1000 living with thalassemia in the United States, but millions more worldwide in countries with poor tracking systems for prevalence. MSD HCT has a high cure rate (>90%) and should be offered to all patients who can avail of this opportunity in childhood when outcomes are best [54 & ,55] . In those who do not, the availability of a donor, stage of the disease, patient age and organ function are critical considerations that drive transplant outcomes [56 & ]. Transplant approaches have evolved in a quest to improve outcomes in alternative donor settings, avoid late toxicities such as gonadal and growth failure, and expose recipients to lower doses of chemotherapy as part of preparative regimen [57, 58] . The acceptance that stable mixed chimerism is able to eradicate disease in the presence of high red cell chimerism is key to the acceptance of RIC transplants and further refinement toward safety [59 & ,60].
Thalassemia
The focus is currently on reducing toxicities with newer preparative regimens and improving outcomes in high-risk (Pesaro risk score 3; hepatomegaly >5 cm in patients >7 years) recipients -DFS is 54% in the former and 24% in the latter risk group [61, 62] -reducing graft rejection rates and expanding donor pools while maintaining outcomes.
Advances in HCT have included decreased graft rejection with the addition of ATG and the incorporation of hydroxyurea, azathioprine and thiotepa into preparative regimens (even with mismatched donors) [63 & ,64]. Treosulfan-based and fludarabinebased MUD HCT in children has reduced toxicity and had good outcomes (82% OS) [65] . Unrelated CBT after ablative busulfan produced good outcomes (73% DFS) in a Taiwanese study [66] . On the basis of registry data from the United States, unrelated donor CBT has inferior results (21% DFS) because of graft rejection and higher treatment related mortality [67] .
RIC regimens are attractive in thalassemia to reduce toxicity and maintain organ function especially if graft rejection is minimized. Recently, a RIC-based trial [Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia (URTH) trial] was completed in the United States and used hydroxyurea, alemtuzumab, fludarabine, melphalan and thiotepa in the conditioning regimen. It enrolled both 8/8 matched marrow and 5-6/6 matched UCBT successfully with 78% DFS and 4% graft rejection [68 & ]. Haploidentical transplants for thalassemia following CD34 selection have reported fair success (14 of 22 DFS; no GVHD) [69] . A recent refinement [8 & ] includes a/bþ T-cell and CD19 þ Bcell depletion with successful engraftment, DFS 91% and TRM 9%. Longer-term follow-up of these patients for late outcomes and immune reconstitution is of interest.
Sickle cell disease
More than 1000 HCT procedures have been performed for SCD to date worldwide. The majority (85%) of transplants reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) registry are from MSDs. Because of improved tracking of long-term disease consequence (cardiopulmonary mortality in the third and fourth decades), there is continued interest in expanding HCT to encompass alternative donors while decreasing SCD-sensitive complicationshepatic sinusoidal obstruction syndrome, posterior reversible encephalopathy syndrome, hypertensive crises, GVHD and endocrine/fertility problems. Reduced-intensity transplants designed to increase tolerability even with underlying disease morbidity have met with early success (95% OS in children; 87% OS in adults) in the MSD setting [58,70 & ]. URD HCT is less utilized in SCD because of the concern for mortality and GVHD. Because cure is the goal, it is logical to consider careful HCT trials in patients with 'severe' disease. Typically, this has been defined as neurologic involvement, chronic debilitating pain or recurrent acute chest syndrome despite intervention, inability to tolerate transfusions and progressive organ damage (eyes, kidneys, joints, etc.) [71] . In any of the above situations, transplant outcomes are likely to be better at a younger age (<16 years) and prior to the development of irreversible organ damage that HCT may not be able to reverse. A MUD transplant trial using RIC (alemtuzumab, fludarabine and melphalan) was completed recently by the Bone Marrow Transplant Clinical Trials Network [Sickle Cell Unrelated Donor Transplant (SCURT) trial] based on our experience with RIC for NMD and is in follow-up for marrow transplants; cord blood transplants were associated with a higher rate of graft rejection with this RIC approach [72] . Limitations to this approach include the paucity of matched voluntary donors for recipients of African origin (16-19%) and the difficulty subjecting recipients to transplant risks prior to the development of significant disease or age progression, which is when outcomes are likely to be better [73 & ]. MUD marrow transplants are planned in an upcoming trial for young adults (age range 15-40 years) using reduced-toxicity conditioning with busulfan, fludarabine and ATG to determine tolerability and outcome (the STRIDE trial). Expansion of donor source is underway. A single-antigen mismatched donor can be identified in 70% of patients [73 & ]. A multi-institution phase I trial utilizing RIC and investigating abatacept-based GVHD prophylaxis is underway with 7/8 matched donors in patients with severe disease who benefit from transplant-based intervention (NCT00920972). Cord blood transplants from URDs resulted in high rates of graft rejection and disease recurrence [67, 72] . To enhance engraftment, immunosuppressive regimens using cord products with higher cell doses (>4.0 Â 10 7 /kg total nucleated cells) are under trial (NCT00920972). Products matched at greater than 5/6 HLA loci are considered acceptable and available to 23% adults and 56% of children in whom utilization is limited by cell dose. Cord expansion strategies [74 & ,75 & ] using notch signaling molecules or nicotinamide are under investigation to optimize cord products for transplant following expansion. Mesenchymal stem cell-facilitated cord transplantation has not yielded an engraftment/survival advantage in the SCD setting [76 & ]. As for haploidentical donors, a RIC approach followed by posttransplant cyclophosphamide was tolerated well with no mortality but had 43% graft rejection, a good start with room for improvement [77] . Haploidentical transplantation is also under investigation for SCD using ablative conditioning and CD34-selected peripheral blood cells [78 & ]. Thus, efforts are ongoing to improve outcomes with both cord and haploidentical transplants to expand donor sources.
As with other hereditary disorders, gene therapy trial efforts for hemoglobinopathies are underway in both Europe and the United States from industry and academic institutions [79 & ,80 & ]. The autologous cells used have no GVHD disadvantage. The safety, durability and level of engraftment to provide longterm benefit will be a key factor to their use.
CONCLUSION
HCT in NMD has become much safer during the past decade, resulting in superior survival rates of even more than 90% in some cases, using unrelated and alternative donors. This has resulted in a dramatically changed life perspective for patients with historically fatal disorders. More importantly, the use of unrelated and alternative donors has made HCT available to many more patients. In some diseases, such as in IEM, unrelated cord blood is the preferred HCT source. In the upcoming years, gene therapy (autologous CD34 þ gene transduced) will become more important for many of the disorders addressed here. This may further reduce toxicity and more importantly may correct the disease better, such as in IEM. As most of these diagnoses are rare disorders, HCT efforts are best as formal cooperative trials. International collaboration is of utmost importance to be able to improve upon existing knowledge and advance the field. 
